Marinus Pharmaceuticals(MRNS) - 2024 Q3 - Quarterly Results
Marinus Pharmaceuticals(MRNS)2024-11-12 21:05
Exhibit 99.1 Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results ● ZTALMY® (ganaxolone) Q3 2024 net product revenue of $8.5 million representing growth of 56% versus Q3 2023 ● Narrowing full year 2024 ZTALMY net product revenue guidance to $33 to $34 million ● Reported results from Phase 3 TrustTSC trial and commenced process to explore strategic alternatives ● Marinus continues to support the commercial growth of ZTALMY; further ganaxolone clinical development ...